A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
A phase 3 trial testing IDRX-42 in gastrointestinal stromal tumour, now recruiting.
Overview
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumours After Imatinib Therapy is a phase 3 interventional study registered as NCT07218926, led by GlaxoSmithKline, and recruiting when checked on 2026-09-11. Official title: A Phase 3, Randomised, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumours (GIST) After Imatinib Therapy (StrateGIST 3). Planned enrolment is 450 participants (estimated). The study started in 2025-12-03 and primary completion is expected in 2028-05-30. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
Shares GSK, Gastrointestinal stromal tumour (GIST) and the tag ctgov-ingest.
- TrialEfficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
Shares GSK and the tag ctgov-ingest.
- TrialEfficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Shares Gastrointestinal stromal tumour (GIST) and the tag ctgov-ingest.
- Trial(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Shares Gastrointestinal stromal tumour (GIST) and the tag ctgov-ingest.
- TreatmentVelzatinib
Shares GSK, Gastrointestinal stromal tumour (GIST) and the tag ctgov-ingest.
- TreatmentNB003
Shares Gastrointestinal stromal tumour (GIST) and the tag ctgov-ingest.
- TreatmentBezuclastinib
Shares Gastrointestinal stromal tumour (GIST) and the tag ctgov-ingest.
- TreatmentCobolimab
Shares GSK and the tag ctgov-ingest.